Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KNEEXO: SF-MSC-EX vs SF-MSC for Degenerative Meniscal Injury
NCT05261360Phase 2Unknown
- Sponsor
- Eskişehir Osmangazi University
- Start
- Mar 2022
- Primary completion
- Mar 2024
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of SF-MSC-EX in degenerative meniscal injury, sponsored by Eskişehir Osmangazi University. Primary endpoint: Evaluation of Knee Functions at 12 months. Status: unknown.
02
Drugs
SF-MSC-EX
03
Conditions
degenerative meniscal injury
Beyond the preview
Go deeper on NCT05261360.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05261360.